JAZZ PHARMACEUTICALS FRANCE

Jazz Pharmaceuticals' Epidyolex failed Phase 3 trial in Japan; British American Tobacco invests in cannabis for growth; DanCann Pharma reports strong Q2 with record revenue and positive EBITDA.

Jazz Pharmaceuticals is a global biopharmaceutical company dedicated to developing life-changing medicines for serious diseases. They are seeking a Manager, Clinical Trial Supply Management (CTSM) to support drug supply activities, inventory management, and vendor coordination. The role requires a Bachelor's degree, clinical trial supply experience, and strong IT skills. Jazz offers competitive compensation and benefits.

FDA approved AstraZeneca's Voydeya for a rare blood disorder. Merck's KRAS inhibitor, MK-1084, enters phase III for NSCLC. Jazz Pharmaceuticals filed for zanidatamab approval for HER2-positive BTC. AstraZeneca and Daiichi Sankyo's ADC, Dato-DXd, under FDA review for breast cancer. Merck's R-DXd in phase II/III for ovarian cancer.

Jazz Pharmaceuticals completes BLA submission for zanidatamab, a HER2-targeted bispecific antibody, seeking accelerated approval for treatment of previously-treated HER2-positive metastatic biliary tract cancer. If approved, zanidatamab would be the first HER2-targeted treatment for this indication in the U.S. The BLA includes data from the Phase 2b HERIZON-BTC-01 trial showing a confirmed objective response rate of 41.3% in HER2-positive BTC patients, with a manageable safety profile.

Ligand Pharmaceuticals reported Q4 2023 adjusted earnings of $1.05 per share, surpassing estimates, with revenues at $28.1M, down 44% due to no COVID-19 Captisol sales. Shares rose 19.9%. Royalty revenues increased to $22.5M, driven by key products. 2024 revenue guidance is $130-$142M, with adjusted EPS expected at $4.25-$4.75. FDA approved Zelsuvmi for molluscum contagiosum, set for 2024 launch.

Zymeworks Inc. updates on 2024-2025 strategic priorities, including zanidatamab's Phase 3 trial data expected in 2024, regulatory reviews, and IND applications for new candidates. With $455M cash resources, the company plans to extend its R&D efforts into 2027, focusing on ADCs and multispecific antibody therapeutics.